These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12385106

  • 1. [Merger of bone biology and immunology].
    Suda T, Shima N, Higashio K.
    Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
    [No Abstract] [Full Text] [Related]

  • 2. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J, Tovar I, Martínez P.
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract] [Full Text] [Related]

  • 3. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S, Nakamura K, Takahasi N, Suda T.
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [Abstract] [Full Text] [Related]

  • 4. Interactions between immune and bone cells: new insights with many remaining questions.
    Lorenzo J.
    J Clin Invest; 2000 Sep; 106(6):749-52. PubMed ID: 10995785
    [No Abstract] [Full Text] [Related]

  • 5. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS.
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
    Hofbauer LC, Heufelder AE, Erben RG.
    J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
    [No Abstract] [Full Text] [Related]

  • 9. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S, Kiyokawa A, Nagayama Y.
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [Abstract] [Full Text] [Related]

  • 10. Crystal structure of RANK ligand involved in bone metabolism.
    Ito S, Hata T.
    Vitam Horm; 2004 Jan; 67():19-33. PubMed ID: 15110169
    [Abstract] [Full Text] [Related]

  • 11. [Osteoporosis induced by immunosuppressant].
    Fukunaga J, Sugahara T.
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():740-3. PubMed ID: 15035219
    [No Abstract] [Full Text] [Related]

  • 12. RANKing intracellular signaling in osteoclasts.
    Feng X.
    IUBMB Life; 2005 Jun; 57(6):389-95. PubMed ID: 16012047
    [Abstract] [Full Text] [Related]

  • 13. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P.
    Circ Res; 2004 Nov 26; 95(11):1046-57. PubMed ID: 15564564
    [Abstract] [Full Text] [Related]

  • 14. Bone versus immune system.
    Arron JR, Choi Y.
    Nature; 2000 Nov 30; 408(6812):535-6. PubMed ID: 11117729
    [No Abstract] [Full Text] [Related]

  • 15. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI.
    Curr Opin Pharmacol; 2004 Aug 30; 4(4):340-6. PubMed ID: 15251126
    [Abstract] [Full Text] [Related]

  • 16. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L, Schwarz EM, Boyce BF.
    Immunol Rev; 2005 Dec 30; 208():19-29. PubMed ID: 16313338
    [Abstract] [Full Text] [Related]

  • 17. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
    Hofbauer LC, Heufelder AE.
    Dtsch Med Wochenschr; 2001 Feb 09; 126(6):145-50. PubMed ID: 11233883
    [No Abstract] [Full Text] [Related]

  • 18. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.
    Cytokine Growth Factor Rev; 2004 Dec 09; 15(6):457-75. PubMed ID: 15561602
    [Abstract] [Full Text] [Related]

  • 19. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K.
    J Cell Physiol; 2004 Oct 09; 201(1):17-25. PubMed ID: 15281085
    [Abstract] [Full Text] [Related]

  • 20. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
    Cozzani M, Giovannini I, Naccari R, Penolazzi L, Lambertini E, Borgatti M, Piva R, Gambari R, Siciliani G.
    Prog Orthod; 2005 Oct 09; 6(2):238-47. PubMed ID: 16276433
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.